The Power of your support is life-changing for those living with AS. It offers essential services and resources that enable them to live seizure-free, improve communication, enjoy better sleep and reduce anxiety. Your generosity ensures they remain healthy and strong, empowering them to lead fuller lives.
ASF funded research advance our understanding of AS and increase the potential for treatment & therapeutics.
FIND OUT MORE
Since her diagnosis, we have relied on the Angelman Syndrome Foundation as a source of information and support.
The Angelman Syndrome Clinic at MGH is a blessing for my adult child. Now we have somebody who really understands our needs.
Amazing things have happened because of the ASF-funded LGIT study from Boston’s MassGeneral Hospital. It was the beginning of a new era for treatments for our children with AS.
Latest press releases, articles and announcements
Ionis Pharmaceuticals has released information regarding their clinical trial of ION582. The trial will move into Phase 3 and will be called Reveal. Ionis will be presenting more information at the FAST Global Science Summit on Saturday, November 9th […]
Read more
Neuren Pharmaceuticals (ASX: NEU) today announced top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Angelman syndrome (AS). Highlights: Clinician and caregiver global efficacy measures specifically designed for Angelman syndrome showed a level of improvement from […]
Read more
Ionis Pharmaceuticals issued a press release today regarding their Phase 1/2a HALOS clinical trial of ION582 for individuals living with Angelman syndrome. Read the Ionis press release here. Livestream Update on July 24 Join the livestream on July 24th at […]
Read more
Today, Ultragenyx Pharmaceuticals shared a press release announcing a “Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome Program.” Read the full press release. Livestream Update on Wednesday, July 24 Tune into the LIVESTREAM updates at the ASF Family Conference on […]
Read more
